Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5279810 | 0.94 | CNR1 (0.42) | CNR1CNR2KDM4E | |
| SCHEMBL2843565 | 0.88 | CNR1 (0.43) | CNR1CNR2KDM4ECHRNB2CHRNA4 | |
| SCHEMBL2846735 | 0.87 | CNR1 (0.38) | CNR1CNR2TP53MDM2 | |
| SCHEMBL2840753 | 0.81 | HPGD (0.42) | CNR1CNR2TP53MDM2 | |
| SCHEMBL2842015 | 0.76 | RAB9A (0.47) | CNR1CNR2 | |
| SCHEMBL2846311 | 0.75 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL5279813 | 0.73 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5272552 | 0.72 | ESR1 (0.37) | KDM4E | |
| SCHEMBL5255417 | 0.71 | CNR1 (0.36) | CNR1CNR2CHRNB2CHRNA4SLC6A2 | |
| Hydrochloric Acid SCHEMBL2845718 | 0.71 | ESR1 (0.36) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | claimed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | claimed |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687537-B2 | N-[(4,5-diphenyl-2-thienyl)methyl]amine derivatives, their preparation and their therapeutic application | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2008-01-10 | — | — | US | disclosed |
| EP-1858872-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006084975-A1 | DERIVATIVES OF N-[(4,5-DIPHENYL-3-ALKYL-2-THIENYL) METHYL] AMINE (AMIDE, THIOUREA AND UREA) AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009543-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 310/4885 |
| US-20100137402-A1 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885KDM4E 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.